Breaking Finance News

HC Wainwright disclosed Proteon Therapeutics Inc (NASDAQ:PRTO), stepping up its target to $18.00 earlier today

Yesterday Proteon Therapeutics Inc (NASDAQ:PRTO) traded 3.80% higher at $8.75. The company’s 50-day moving average is $9.10 and its 200-day moving average is $7.91. The last closing price is up 10.56% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 8,536 shares of PRTO traded hands, down from an avg. volume of 31,439

HC Wainwright raised the target price of Proteon Therapeutics Inc (NASDAQ:PRTO) to $18.00 stating a potential upside of 1.06%.

Previously on 04/14/2016, Robert W. Baird reported on Proteon Therapeutics Inc (NASDAQ:PRTO) increased the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 1.39%.

See Chart Below

Proteon Therapeutics Inc (NASDAQ:PRTO)

Proteon Therapeutics Inc has a 52 week low of $4.90 and a 52 week high of $17.76 The company’s market cap is currently $0.

In addition to HC Wainwright reporting its target price, a total of 5 brokers have issued a report on the stock. The consensus target price is $21.40 with 2 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Proteon Therapeutics Inc (NASDAQ:PRTO)

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *